Acute Sensorineural Hearing Loss - Pipeline Review, H2 2016

Global Markets Direct’s, ‘Acute Sensorineural Hearing Loss - Pipeline Review, H2 2016’, provides an overview of the Acute Sensorineural Hearing Loss pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Sensorineural Hearing Loss, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Sensorineural Hearing Loss and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Acute Sensorineural Hearing Loss

The report reviews pipeline therapeutics for Acute Sensorineural Hearing Loss by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Acute Sensorineural Hearing Loss therapeutics and enlists all their major and minor projects

The report assesses Acute Sensorineural Hearing Loss therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Acute Sensorineural Hearing Loss

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Acute Sensorineural Hearing Loss

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Acute Sensorineural Hearing Loss pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Nordmark Arzneimittel GmbH & Co. KG

Orbis Biosciences Inc

Otologic Pharmaceutics, Inc.

Pragma Therapeutics

Xigen SA

Nordmark Arzneimittel GmbH & Co. KG

Orbis Biosciences Inc

Otologic Pharmaceutics, Inc.

Pragma Therapeutics

Xigen SA

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Acute Sensorineural ...

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Acute Sensorineural Hearing Loss Overview 6

Therapeutics Development 7

Pipeline Products for Acute Sensorineural Hearing Loss - Overview 7

Acute Sensorineural Hearing Loss - Therapeutics under Development by Companies 8

Acute Sensorineural Hearing Loss - Pipeline Products Glance 9

Late Stage Products 9

Clinical Stage Products 10

Early Stage Products 11

Acute Sensorineural Hearing Loss - Products under Development by Companies 12

Acute Sensorineural Hearing Loss - Companies Involved in Therapeutics Development 13

Nordmark Arzneimittel GmbH & Co. KG 13

Orbis Biosciences Inc 14

Otologic Pharmaceutics, Inc. 15

Pragma Therapeutics 16

Xigen SA 17

Acute Sensorineural Hearing Loss - Therapeutics Assessment 18

Assessment by Monotherapy Products 18

Assessment by Combination Products 19

Assessment by Target 20

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Drug Profiles 28

(acetylcysteine + disufenton sodium) - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

ancrod - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

betamethasone valerate ER - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

OR-102 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Otopotin - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Otostem - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

Small Molecules for Sensorineural Hearing Loss - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Small Molecules to Agonize mGlu7 for Acute Sensorineural Hearing Loss - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Small Molecules to Inhibit Gamma Secretase for Sensorineural Hearing Loss - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

XG-102 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Acute Sensorineural Hearing Loss - Dormant Projects 42

Acute Sensorineural Hearing Loss - Product Development Milestones 43

Featured News & Press Releases 43

Jun 17, 2016: Auris Medical Initiates ASSENT Phase 3 Trial of AM-111 for Treatment of Sudden Deafness 43

Nov 13, 2015: Auris Medical Announces Enrollment of First Patient in HEALOS Study of AM-111 in Treatment of Idiopathic Sudden Sensorineural Hearing Loss 43

Jun 25, 2015: Auris Medical and Cochlear to Collaborate on Clinical Trial with AM-111 for Otoprotection during Cochlear Implant Surgery 44

May 04, 2015: Auris Medical Provides Update on Clinical Development Plan for AM-111 44

Nov 19, 2014: Otologic Pharmaceutics Initiates Phase 1 Clinical Study of NHPN-1010 for Hearing Disorders 45

Nov 13, 2012: Auris Medical Announces Positive Results From Phase IIb Trial With AM-111 For Treatment Of Acute Sensorineural Hearing Loss 46

Apr 20, 2012: Auris Medical Completes Enrolment In Phase IIb Trial With AM-111 For Treatment Of Acute Sensorineural Hearing Loss 46

Appendix 47

Methodology 47

Coverage 47

Secondary Research 47

Primary Research 47

Expert Panel Validation 47

Contact Us 47

Disclaimer 48

List of Tables

List of Tables

Number of Products under Development for Acute Sensorineural Hearing Loss, H2 2016 7

Number of Products under Development by Companies, H2 2016 ...

List of Tables

Number of Products under Development for Acute Sensorineural Hearing Loss, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Late Stage Development, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 10

Comparative Analysis by Early Stage Development, H2 2016 11

Products under Development by Companies, H2 2016 12

Acute Sensorineural Hearing Loss - Pipeline by Nordmark Arzneimittel GmbH & Co. KG, H2 2016 13

Acute Sensorineural Hearing Loss - Pipeline by Orbis Biosciences Inc, H2 2016 14

Acute Sensorineural Hearing Loss - Pipeline by Otologic Pharmaceutics, Inc., H2 2016 15

Acute Sensorineural Hearing Loss - Pipeline by Pragma Therapeutics, H2 2016 16

Acute Sensorineural Hearing Loss - Pipeline by Xigen SA, H2 2016 17

Assessment by Monotherapy Products, H2 2016 18

Assessment by Combination Products, H2 2016 19

Number of Products by Stage and Target, H2 2016 21

Number of Products by Stage and Mechanism of Action, H2 2016 23

Number of Products by Stage and Route of Administration, H2 2016 25

Number of Products by Stage and Molecule Type, H2 2016 27

Acute Sensorineural Hearing Loss - Dormant Projects, H2 2016 42

List of Figures

List of Figures

Number of Products under Development for Acute Sensorineural Hearing Loss, H2 2016 7

Number of Products under Development by Companies, H2 2016 ...

List of Figures

Number of Products under Development for Acute Sensorineural Hearing Loss, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Clinical Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy Products, H2 2016 18

Number of Products by Targets, H2 2016 20

Number of Products by Stage and Targets, H2 2016 20

Number of Products by Mechanism of Actions, H2 2016 22

Number of Products by Stage and Mechanism of Actions, H2 2016 22

Number of Products by Routes of Administration, H2 2016 24

Number of Products by Stage and Routes of Administration, H2 2016 24

Number of Products by Molecule Types, H2 2016 26

Number of Products by Stage and Molecule Types, H2 2016 26

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports